Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Acute Hepatitis
11%
Antibody Conjugate
18%
Bacterium
7%
Bioavailability
15%
Bloodstream Infection
46%
Breast Cancer
9%
Burkholderia Cepacia Complex
46%
Burkholderia Cepacia Infection
7%
Candida
46%
Candida albicans
35%
Candida parapsilosis
23%
Candida tropicalis
11%
Candidemia
46%
Candidiasis
11%
Carbon Nanotube
18%
Clinical Trial
9%
Controlled Release
9%
Cytotoxicity
9%
Dendrimer
18%
Electric Shock
15%
Enzyme-Linked Immunosorbent Assay
5%
Glioblastoma
46%
Hematologic Disease
5%
Hepatitis E Virus
93%
Immunocompromised Patient
11%
Immunoglobulin M Antibody
11%
Infection
29%
Malignant Neoplasm
33%
Mammalian Target of Rapamycin
46%
Mammalian Target of Rapamycin Complex 1
7%
Mating Hormone Alpha Factor
46%
Median Survival Time
11%
microRNA
46%
Mortality Rate
23%
Nanocarrier
18%
Nanomedicine
5%
Nanoparticle
28%
Natural Product
9%
Passive Targeting
18%
Pentetrazole
15%
Phosphatidylinositol 3 Kinase
46%
Piracetam
46%
Prevalence
58%
Prospective Study
11%
Resistance to Antifungal Agent
23%
Seroprevalence
11%
Tonic Clonic Seizure
46%
Triple Negative Breast Cancer
46%
Virus Infection
46%
Virus RNA
11%
Immunology and Microbiology
Antifungal Resistance
13%
Antifungal Susceptibility
13%
Blood Level
9%
Blood Plasma
18%
Blood Product
11%
Blood Transfusion
11%
Burkholderia cepacia
5%
Burkholderia Cepacia Complex
46%
Cancer Immunotherapy
46%
Candida
46%
Candida albicans
19%
Candida krusei
13%
Candida parapsilosis
13%
Candida tropicalis
6%
Dipeptidyl Peptidase IV
93%
ELISA
21%
Enterobacterales
93%
Etest
15%
Immune Escape
23%
Immunocompromised Patient
11%
Immunoglobulin G
11%
Immunoglobulin M Antibody
23%
Immunotherapy
23%
Infection
84%
Microbiology
6%
Middle East Respiratory Syndrome Coronavirus
93%
Minimum Inhibitory Concentration
14%
Mortality Rate
13%
Multiplex Polymerase Chain Reaction
15%
Prevalence
100%
Reverse Transcription Polymerase Chain Reaction
11%
Ribonucleic Acid
23%
Seroprevalence
23%
Single Nucleotide Polymorphism
18%
Susceptibility
23%
Viral Disease
93%
Virus
18%
Medicine and Dentistry
Acetylcholinesterase
18%
All Cause Mortality
15%
Alzheimer's Disease
93%
Anemia
15%
Antibiogram
15%
Antibiotic Resistance
46%
Antibiotic Therapy
24%
Artificial Respiration
9%
Bloodstream Infection
24%
Carbapenem Derivative
18%
Ceftazidime
24%
Central Venous Catheter
9%
Clinical Significance
9%
Cognitive Decline
18%
Cohort Studies
9%
Cohort Study
15%
Comorbidity
9%
Cystic Fibrosis
56%
Dextro Aspartic Acid
18%
Dietary Pattern
18%
Hospital Infection
15%
Immunocompromised Patient
9%
Infection
93%
Infection Control
9%
Infection Prevention
15%
Intensive Care Unit
15%
Leukocytosis
15%
Levofloxacin
24%
Lifestyle Modification
18%
Logistic Regression Analysis
24%
Mortality Rate
9%
Neurodegeneration
37%
Neurotransmitter
93%
Pathogen
9%
Pathology of Alzheimer's Disease
18%
Piperacillin/Tazobactam
9%
Primary Outcome
15%
Quinolone Derivative
9%
Receptor
18%
Recurrence Risk
9%
Recurrent Disease
15%
Stenotrophomonas maltophilia
46%
Survival Estimate
9%
Targeted Therapy
18%
Tau Protein
18%
Tertiary Care
9%
Thrombocytopenia
15%
Treatment Outcome
9%
Trimethoprim/Sulfamethoxazole
24%
Ventilator-Associated Pneumonia
9%